Phytoplant Research S.L. and CTT Announce Collaboration
Toronto, Ontario / TheNewswire / August 10, 2015 -- The Board of Directors of Mindesta Inc. (OTCBB: MDST) is pleased to announce the collaboration between CTT Pharmaceutical Holdings Inc and Phytoplant Research, S.L.. Phytoplant Resesarch S.L. will provide CTT Pharmaceuticals Inc., novel unique extracts from their proprietary Cannabis varieties to manufacture novel quick dissolving oral wafers that offer the entourage therapeutic effects of the complete phytocomplex of Cannabis, for indications such as chronic pain management, epilepsy, psoriasis, and cancer.
The unique extracts will include highly purified phytocannabinoids like THC, CBD, CBG, CBC and CBN and combination products, such as THC:CBD with specific ratios, for example a 1:1 ratio. Phytoplant Resesarch S.L. agreed also to provide the necessary expertise related to the development of new highly purified phytocannabinoid formulations for oromucosal dosage wafers and their specific indications.
CTT Pharmaceuticals Inc. and Phytoplant Resesarch S.L. are also planning to work on a structured plan to conduct some fundamental clinical studies in Europe to prove the bioavailability of the active compounds in the wafers and show their efficacy for specific indications. Furthermore Phytoplant Resesarch S.L. has agreed to collaborate with CTT Pharmaceuticals Inc. to handle regulatory matters and facilitate the registration process in Europe for future marketing and distribution of various cannabinoids drug delivery systems.
Phytoplant expertise and knowledge of extraction techniques to make compounds with extremely high purity of 99% will be useful in developing our oral films to treat various diseases with greater precision as the control on the dosage will be very quantitative and accurate and the overdosing will be avoided which is most frequent case with the smoking. In order to fulfill our ultimate goal of improving delivery and creating better adherence and safety for cannabis opioids, CTT plans to collaborate and establish joint ventures with variety of specific cross industry skill sets. To this end, as we continue to build our team, expertise brings unique and invaluable asset to CTT Pharmaceuticals by opening a door to deliver precise dosing of the necessary cannabinoids." said Dr. Pankaj Modi, CEO and President- CTT Pharmaceuticals.
ABOUT PHYTOPLANT RESEARCH S.L.
Phytoplant Research S.L.is a privately-owned Spanish company founded in 2008 and active in the field of phytotherapy research. The company specializes in developing the industrial chain of medicinal plants, from selection and breeding to registration (for example, at CPVO), cultivation of registered varieties and obtaining derived products. Phytoplant Research S.L. focuses on research and development products that contain plant material and extracts, as well as essential and seed oils. These products represent significant economic potential for the Pharmaceutical, Nutraceutical and Dermocosmetic industries.
ABOUT CTT PHARMACEUTICALS:
CTT Pharma has invented and developed an ideal intra-oral, sublingual, fast-dissolving wafer drug delivery system, complete with a mobile backend tracking software designed to increase patient compliance and prevent physical addiction.
CTT Pharma's principal asset is a patented, orally administered, fast dissolving wafer (the "Wafer")
The Wafer formulation is protected by Canadian Patent Number CA 2624110 C and US Patent Number 8,823,401 B2. The Canadian Patent, is a blanket patent covering most pharmaceutical agents (an open patent) and US Patent consist of approved opiates; such as Fentanyl, Morphine, Codeine etc.
CTT Pharma's primary mission is to lower addiction and improve overall compliance within the pain management market, specifically opiates, through the use of improved drug delivery and novel IT technology. This technology platform will be targeting both the human and pet (Veterinarian) markets.
CTT Pharma's Oral fast dissolving drug delivery systems will consist of films and wafers that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system, mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficiency of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing.
Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its technology will be the first to gain widespread use in major markets such as Pain Management: Medicinal Marijuana(Cannawafe); Veterinary (VetWafe); Medicine/Pharmaceutical (MedWafe), and Topical Creams.
For more information, please visit our website: www.cttpharmaceuticals.com
Copyright (c) 2015 TheNewswire - All rights reserved.